



	2015			2016			2017			2018		
	Patient	Concurrent	Concurrency	Patients	Concurrent	Concurrency	Patients	Concurrent	Concurrency	Patients	Concurrent	Concurrency
	Counts	Patients	%	Counts	Patients	%	Counts	Patients	%	Counts	Patients	%
ADHD Stimulants	9,945,909	980,070	10%	10,643,095	1,222,857	11%	10,794,386	1,274,385	12%	10,938,173	1,303,764	12%
0-5 years	118,600	13,112	11%	160,246	22,955	14%	197,131	31,345	16%	230,716	39,397	17%
6-11 years	2,162,770	194,858	9%	2,443,992	249,167	10%	2,634,526	272,127	10%	2,783,752	288,592	10%
12-17 years	1,959,828	225,092	11%	1,915,696	246,138	13%	1,775,858	226,709	13%	1,630,719	202,788	12%
18-64 years	5,508,936	523,872	10%	5,921,784	676,367	11%	5,989,812	715,564	12%	6,102,970	745,175	12%
65 yrs and older	196,629	23,241	12%	203,615	28,569	14%	200,177	29,015	14%	195,627	28,442	15%
Unspecified age	230	26	11%	232	33	14%	224	28	12%	220	24	11%
ADHD Stimulant Drug Groups												
Amphetamines	6,668,107	604,079	9%	7,257,218	776,403	11%	7,434,013	822,880	11%	7,616,652	853,073	11%
Methylphenidate Products	3,581,119	363,824	10%	3,681,644	428,676	12%	3,623,037	427,880	12%	3,539,668	419,648	12%
Atomoxetine	547,195	99,513	18%	596,648	123,125	21%	617,773	129,323	21%	667,071	139,159	21%
SGAs	7,138,758	980,070	14%	8,862,629	1,222,857	14%	9,341,801	1,274,385	14%	9,579,463	1,303,764	
0-5 years	26,825	13,112	49%	40,963	22,955	56%	51,633	31,345	61%	62,141	39,397	63%
6-11 years	309,736	194,858	63%	392,688	249,167	63%	434,059	272,127	63%	468,884	288,592	62%
12-17 years	557,080	225,092	40%	653,726	246,138	38%	663,932	226,709	34%	664,869	202,788	31%
18-64 years	5,156,751	523,872	10%	6,442,683	676,367	10%	6,793,669	715,564	11%	6,951,714	745,175	11%
65 yrs and older	1,090,436	23,241	2%	1,334,922	28,569	2%	1,400,648	29,015	2%	1,436,578	28,442	2%
Unspecified age	235	26	11%	269	33	12%	341	28	8%	365	24	7%

Source: Symphony Health Integrated Dataverse®. Data years 2015-2018. Data extracted Dec 2019.

ADHD=Attention Deficit Hyperactivity Disorder, FGA=first-generation antipsychotic

Concurrent therapy defined as at least one day overlap between ADHD stimulant and FGA therapy episodes